A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Summary

This is a first-in-human study of BMS-986506 in participants with advanced Clear Cell Renal Cell Carcinoma (ccRCC). The primary objective of this study is to find out if BMS-986506 is safe and can be tolerated when taken alone or in combination by participants with ccRCC.

Eligibility

Inclusion Criteria

* Participants must have histologically confirmed diagnosis of locally advanced or metastatic ccRCC.
* For part 1: Participants must have already had at least two different treatment plans in the past, including immunotherapy and a targeted therapy.
* For part 2: Participants must have had at least one standard treatment plan that included both a PD-1/L1 inhibitor and a VEGF-TKI (either together or one after the other).
* Part 3: Participants must have had at least 1 standard treatment regimen (including a PD-1/L1 checkpoint inhibitor and/or a VEGF-TKI).
* Part 4: Participants must not have received prior systemic therapy for metastatic RCC, but may have received prior adjuvant therapy for completely resected RCC with PD-1 inhibitor if recurrence occurred at least 6 months after the last dose of adjuvant or neoadjuvant therapy.
* Eastern Cooperative Oncology Group performance status of 0 to 1.

Exclusion Criteria

* Inability to administer and/or tolerate oral medication without chewing, breaking, crushing, or otherwise altering the product dosage form.
* Part 2A: Participants who have received more than 3 prior systemic regimens for locally advanced or metastatic ccRCC including prior treatment with HIF2a inhibitors.
* Part 2A and Part 4: Participants who have received prior treatment with belzutifan (or another HIF2a inhibitor).
* Part 3B and Part 4B: Participants who have received prior ipilimumab (or another anti-CTLA-4 containing antibody).
* Participants who have hypoxia as defined by a pulse oximeter reading \< 92% at rest or requires intermittent or chronic supplemental oxygen.
* Participants who have received colony-stimulating factors (eg, G-CSF, GM-CSF or recombinant EPO) within 28 days prior to the first dose of study intervention.
* Part 3 and Part 4: Participants with a history of Grade ≥3 immune-mediated AEs leading to discontinuation of prior immunotherapy.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Conditions2

Interventions3

Locations5 sites

Find trials near these locations

Related trials

• Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma — Gustave Roussy, Cancer Campus, Grand Paris
• Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) — Melanoma Institute Australia
• CARE1 Pragmatic Clinical Trial — Gustave Roussy, Cancer Campus, Grand Paris
• Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie — Isala
• Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia — Institute of Oncology Ljubljana
• Immunotherapy in Patients With Early dMMR Rectal Cancer — Odense University Hospital
• Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma — The Netherlands Cancer Institute
• MAQ-001 in Patients With Advanced Solid Tumors — MabQuest SA

Browse More Trials